Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice

NMR in Biomedicine

Volumn 26, Issue 12, 2013, Pages 1742-1750

  Wang, Xiaojie ^a   Brieland, Joan K ^b   Kim, Joong H ^c   Chen, Ying Jr ^a   O'Neal, Janet ^b   O'Neil, Shawn P ^b   Tu, Tsang Wei ^d   Trinkaus, Kathryn ^a   Song, Sheng Kwei ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Axial diffusivity; Axonal injury; Demyelination; Diffusion tensor imaging; Experimental autoimmune encephalomyelitis; FTY720; Multiple sclerosis; Radial diffusivity

Indexed keywords

AXIAL DIFFUSIVITY; AXONAL INJURY; DEMYELINATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FTY720; MULTIPLE SCLEROSIS; RADIAL DIFFUSIVITY;

DIFFUSION; DIFFUSION TENSOR IMAGING; DISEASE CONTROL; DISEASES; MAGNETIC RESONANCE IMAGING; MAMMALS;

TENSORS;

FINGOLIMOD; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE SEVERITY; FEMALE; IMMUNIZATION; LUMBAR SPINAL CORD; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION; WHITE MATTER;

MUS;

AXIAL DIFFUSIVITY; AXONAL INJURY; DEMYELINATION; DIFFUSION TENSOR IMAGING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FTY720; MULTIPLE SCLEROSIS; RADIAL DIFFUSIVITY;

ANIMALS; ANISOTROPY; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; MYELIN BASIC PROTEIN; PROPYLENE GLYCOLS; SPHINGOSINE; SPINE;

EID: 84888025913     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3012     Document Type: Article

References (56)

1. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol. Clin. 1996; 14(2): 291-308.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000; 343(13): 938-952.
3. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain, 2000; 123(Pt 6): 1174-1183.
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 2008; 31: 247-269.
5. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann. Neurol. 2007; 62(4): 314-326.
6. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362(5): 402-415.
7. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler. 2010; 16(2): 197-207.
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362(5): 387-401.
9. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, Group FDS. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology, 2009; 72(1): 73-79.
10. Balatoni B, Storch MK, Swoboda EM, Schonborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 2007; 74(5): 307-316.
11. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA, 2011; 108(2): 751-756.
12. Rossi S, Lo Giudice T, De Chiara V, Musella A, Studer V, Motta C, Bernardi G, Martino G, Furlan R, Martorana A, Centonze D. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br. J. Pharmacol. 2012; 165(4): 861-869.
13. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 2007; 323(2): 469-475.
14. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009; 19(2): 254-266.
15. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008; 274(1-2): 13-17.
16. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010; 33(2): 91-101.
17. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 2010; 6(7): 373-382.
18. Kipp M, Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult. Scler. 2012; 18(3): 258-263.
19. Kim HJ, Miron VE, Dukala D, Proia RL, Ludwin SK, Traka M, Antel JP, Soliven B. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. Faseb J. 2011; 25(5): 1509-1518.
20. Sheridan GK, Dev KK. S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia, 2012; 60(3): 382-392.
21. Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J. Neuroinflammation, 2011; 8: 76.
22. Rau CR, Hein K, Sattler MB, Kretzschmar B, Hillgruber C, McRae BL, Diem R, Bahr M. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Am. J. Pathol. 2011; 178(4): 1770-1781.
23. Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult. Scler. 2011; 17(8): 939-948.
24. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage, 2002; 17(3): 1429-1436.
25. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage, 2003; 20(3): 1714-1722.
26. Budde MD, Xie M, Cross AH, Song SK. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis. J. Neurosci. 2009; 29(9): 2805-2813.
27. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011; 69(5): 759-777.
28. Kim JH, Budde MD, Liang HF, Klein RS, Russell JH, Cross AH, Song SK. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol. Dis. 2006; 21(3): 626-632.
29. Garbow JR, Mcintosh C, Conradi MS. Actively decoupled transmit-receive coil-pair for mouse brain MRI. Concepts Magn. Reson. Part B, Magn. Reson. Eng. 2008; 33B(4): 252-259.
30. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 1992; 32(6): 758-766.
31. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging, 2004; 20(1): 16-24.
32. Traboulsee A, Li DK. Conventional MR imaging. Neuroimaging Clin. N. Am. 2008; 18(4): 651-673, x.
33. Budde MD, Kim JH, Liang HF, Russell JH, Cross AH, Song SK. Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed. 2008; 21(6): 589-597.
34. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol. Appl. Neurobiol. 1978; 4(2): 151-162.
35. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain, 1996; 119(Pt 3): 701-708.
36. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J. Neurol. Neurosurg. Psychiatry, 2003; 74(8): 1090-1094.
37. Xu J, Sun SW, Naismith RT, Snyder AZ, Cross AH, Song SK. Assessing optic nerve pathology with diffusion MRI: from mouse to human. NMR Biomed. 2008; 21(9): 928-940.
38. Klawiter EC, Xu J, Naismith RT, Benzinger TL, Shimony JS, Lancia S, Snyder AZ, Trinkaus K, Song SK, Cross AH. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared to multiple sclerosis. Mult. Scler. 2012; 18(9): 1259-1268.
39. Benedetti B, Rocca MA, Rovaris M, Caputo D, Zaffaroni M, Capra R, Bertolotto A, Martinelli V, Comi G, Filippi M. A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry, 2010; 81(1): 26-30.
40. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG, McDonald WI, Miller DH. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology, 1993; 43(12): 2632-2637.
41. Hesseltine SM, Law M, Babb J, Rad M, Lopez S, Ge Y, Johnson G, Grossman RI. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. Am. J. Neuroradiol. 2006; 27(6): 1189-1193.
42. Ohgiya Y, Oka M, Hiwatashi A, Liu X, Kakimoto N, Westesson PL, Ekholm SE. Diffusion tensor MR imaging of the cervical spinal cord in patients with multiple sclerosis. Eur. Radiol. 2007; 17(10): 2499-2504.
43. Wheeler-Kingshott CA, Hickman SJ, Parker GJ, Ciccarelli O, Symms MR, Miller DH, Barker GJ. Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage, 2002; 16(1): 93-102.
44. van Hecke W, Nagels G, Emonds G, Leemans A, Sijbers J, van Goethem J, Parizel PM. A diffusion tensor imaging group study of the spinal cord in multiple sclerosis patients with and without T2 spinal cord lesions. J. Magn. Reson. Imaging, 2009; 30(1): 25-34.
45. Klawiter EC, Schmidt RE, Trinkaus K, Liang HF, Budde MD, Naismith RT, Song SK, Cross AH, Benzinger TL. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage, 2011; 55(4): 1454-1460.
46. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009; 158(5): 1173-1182.
47. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 2002; 14(5): 569-575.
48. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 2004; 73: 321-354.
49. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 2007; 323(2): 626-635.
50. Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, Traynelis SF, Hepler JR. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol. 2003; 64(5): 1199-1209.
51. Buccoliero R, Futerman AH. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacol. Res. 2003; 47(5): 409-419.
52. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 2002; 3(9): 705-714.
53. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, Antel JP, Soliven B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia, 2007; 55(16): 1656-1667.
54. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. Faseb J. 2007; 21(7): 1503-1514.
55. Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 2008; 173(4): 1143-1152.
56. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 2008; 63(1): 61-71.